86 results
Page 2 of 5
424B5
61bu anqwpq0
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
cgxx969 cjrg4qhzq
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
6bsazosbs707 mznyn
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
aw25hsayys4xl
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
5l932pxhkihvq4q5z9
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
hcllvqee7kc hf
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
xsw2865io1gv60m0yw
12 Apr 21
Prospectus supplement
1:44pm
S-3
p4dltjj1zc
2 Apr 21
Shelf registration
12:00am
8-K
EX-10.1
m4fwo
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
y6rva
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
mvlpib0g
5 Oct 20
Prospectus supplement with pricing info
4:16pm